| 101 |
33328764 | Quantitative Tyrosine Phosphoproteomic Analysis of Resistance to Radiotherapy in Nasopharyngeal Carcinoma Cells. | 2020 |
1 |
| 102 |
30198788 | Alpha 2-Adrenergic Receptor Agonist Brimonidine Stimulates ERK1/2 and AKT Signaling via Transactivation of EGF Receptors in the Human MIO-M1 Müller Cell Line. | 2019 Jan |
2 |
| 103 |
30273693 | PAC1 regulates receptor tyrosine kinase transactivation in a reactive oxygen species-dependent manner. | 2019 Oct |
1 |
| 104 |
30401746 | Regulation of Connexin32 by ephrin receptors and T-cell protein-tyrosine phosphatase. | 2019 Jan 4 |
2 |
| 105 |
30462558 | Crosstalk between TF/FVIIa and EGFR signaling in colorectal cancer cells. | 2019 |
1 |
| 106 |
30474276 | Gelatin nonwovens-based epithelial morphogenesis involves a signaling axis comprising EGF-receptor, MAP kinases ERK 1/2, and β1 integrin. | 2019 Mar |
2 |
| 107 |
30521970 | The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104). | 2019 Mar |
1 |
| 108 |
30604896 | GRB7 dependent proliferation of basal-like, HER-2 positive human breast cancer cell lines is mediated in part by HER-1 signaling. | 2019 May |
1 |
| 109 |
30910997 | Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence. | 2019 Mar 25 |
2 |
| 110 |
31075398 | Angio-associated migratory cell protein interacts with epidermal growth factor receptor and enhances proliferation and drug resistance in human non-small cell lung cancer cells. | 2019 Sep |
1 |
| 111 |
31083325 | Grb7, a Critical Mediator of EGFR/ErbB Signaling, in Cancer Development and as a Potential Therapeutic Target. | 2019 May 10 |
2 |
| 112 |
31110287 | EGFR is required for Wnt9a-Fzd9b signalling specificity in haematopoietic stem cells. | 2019 Jun |
1 |
| 113 |
31243371 | UDP-glucose accelerates SNAI1 mRNA decay and impairs lung cancer metastasis. | 2019 Jul |
1 |
| 114 |
31374910 | Targeting Degradation of EGFR through the Allosteric Site Leads to Cancer Cell Detachment-Promoted Death. | 2019 Aug 1 |
1 |
| 115 |
31395339 | Type II cGMP-dependent protein kinase phosphorylates EGFR at threonine 669 and thereby inhibits its activation. | 2019 Oct 8 |
2 |
| 116 |
31485130 | Networking of predicted post-translational modification (PTM) sites in human EGFR. | 2019 |
3 |
| 117 |
31543779 | Triple Trouble: A Case of Multiple Resistance Mechanisms after First Generation EGFR-TKI in NSCLC. | 2019 May-Aug |
2 |
| 118 |
31554377 | Targeting Epidermal Growth Factor Receptor by MiRNA-145 Inhibits Cell Growth and Sensitizes NSCLC Cells to Erlotinib. | 2019 Sep 1 |
1 |
| 119 |
31554698 | Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines. | 2019 Dec |
2 |
| 120 |
31561203 | Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy. | 2019 Nov |
1 |
| 121 |
31564718 | Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. | 2019 Oct |
2 |
| 122 |
31568888 | Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). | 2019 Nov |
3 |
| 123 |
31570733 | Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance -A Multicenter Randomized Trial. | 2019 Sep 30 |
1 |
| 124 |
31571631 | A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients. | 2019 Jul |
2 |
| 125 |
31571924 | Epidermal growth factor receptor (EGFR) gene alteration and protein overexpression in Malaysian triple-negative breast cancer (TNBC) cohort. | 2019 |
3 |
| 126 |
31584260 | Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma. | 2019 Oct 16 |
1 |
| 127 |
31584455 | Efficacy of gefitinib at reduced dose in EGFR mutant non-small cell lung carcinoma. | 2019 Nov |
2 |
| 128 |
31584970 | Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease. | 2019 |
2 |
| 129 |
31585087 | Oncogenic Mutations Rewire Signaling Pathways by Switching Protein Recruitment to Phosphotyrosine Sites. | 2019 Oct 3 |
1 |
| 130 |
31587882 | Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. | 2019 Dec |
2 |
| 131 |
31595714 | Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors. | 2019 Dec |
6 |
| 132 |
31598253 | Liquid chromatography-tandem mass spectrometry metabolic profiling of nazartinib reveals the formation of unexpected reactive metabolites. | 2019 Aug |
2 |
| 133 |
31608233 | Double-Stranded DNA in Exosomes of Malignant Pleural Effusions as a Novel DNA Source for EGFR Mutation Detection in Lung Adenocarcinoma. | 2019 |
2 |
| 134 |
31609054 | Site-Specific Encoding of Photoactivity in Antibodies Enables Light-Mediated Antibody-Antigen Binding on Live Cells. | 2019 Dec 9 |
1 |
| 135 |
31614143 | Neurotensin receptors regulate transactivation of the EGFR and HER2 in a reactive oxygen species-dependent manner. | 2019 Dec 15 |
3 |
| 136 |
31616716 | Histopathological Features of Drug-Induced Liver Injury Secondary to Osimertinib. | 2019 Feb |
1 |
| 137 |
31619200 | STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers. | 2019 Oct 16 |
3 |
| 138 |
31620244 | Comparison of different semi-automated cfDNA extraction methods in combination with UMI-based targeted sequencing. | 2019 Oct 1 |
1 |
| 139 |
31621403 | Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer. | 2019 Dec |
2 |
| 140 |
31632080 | Therapeutic Effect Of First-Line EGFR-TKIs Combined With Concurrent Cranial Radiotherapy On NSCLC Patients With EGFR Activating Mutation And Brain Metastasis: A Retrospective Study. | 2019 |
1 |
| 141 |
31636509 | (-)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells. | 2019 |
2 |
| 142 |
31637005 | EGFR TKIs impair lysosome-dependent degradation of SQSTM1 to compromise the effectiveness in lung cancer. | 2019 |
2 |
| 143 |
31642175 | Osimertinib 160 mg daily for advanced non-small cell lung cancer with leptomeningeal metastasis: A case report. | 2019 Oct |
2 |
| 144 |
31644442 | Intrapatient Molecular and Histologic Heterogeneity After First-generation or Second-generation TKI Therapy of NSCLC Patients: Potential Clinical Impact on Subsequent third-generation TKI Treatment. | 2019 Nov |
2 |
| 145 |
31648503 | [Efficacy of first generation EGFR-TKIs and chemotherapy as first-line therapy in advanced lung adenocarcinoma patients with uncommon EGFR mutations]. | 2019 Oct 23 |
1 |
| 146 |
31653451 | Homo- and Heteroassociations Drive Activation of ErbB3. | 2019 Nov 19 |
1 |
| 147 |
31656643 | Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR-mutated lung cancer patients. | 2019 Sep |
4 |
| 148 |
31671561 | FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management. | 2019 Oct 30 |
3 |
| 149 |
31673738 | Co-delivery of GOLPH3 siRNA and gefitinib by cationic lipid-PLGA nanoparticles improves EGFR-targeted therapy for glioma. | 2019 Nov |
1 |
| 150 |
31681582 | EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies. | 2019 |
1 |